Pathophysiology of Septic Shock

被引:91
|
作者
Russell, James A. [1 ]
Rush, Barret [2 ]
Boyd, John [1 ]
机构
[1] St Pauls Hosp, Ctr Heart Lung Innovat, Dept Med, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada
[2] St Pauls Hosp, Div Crit Care Med, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada
关键词
Septic shock; Sepsis; Vasodilation; Permeability; Cardiac dysfunction; Contractility; Nitric oxide; Cytokines; LEFT-VENTRICULAR CONTRACTILITY; NECROSIS-FACTOR-ALPHA; ACTIVATED PROTEIN-C; GOAL-DIRECTED RESUSCITATION; HEPARIN-BINDING PROTEIN; NITRIC-OXIDE SYNTHESIS; LOW-DOSE VASOPRESSIN; SPHINGOSINE; 1-PHOSPHATE; CARDIAC MYOCYTES; HYDROXYETHYL STARCH;
D O I
10.1016/j.ccc.2017.08.005
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The fundamental features of septic shock are vasodilation, increased permeability, hypovolemia, and ventricular dysfunction. Vasodilation owing to increased nitric oxide and prostaglandins is treated with vasopressors (norepinephrine first). Increased permeability relates to several pathways (Slit/Robo4, vascular endothelial growth factor, angiopoietin 1 and 2/Tie2 pathway, sphingosine-1-phosphate, and heparin-binding protein), some of which are targets for therapies. Hypovolemia is common, and crystalloid is recommended for fluid resuscitation. Cardiomyocyte-inflammatory interactions decrease contractility, and dobutamine is recommended to increase cardiac output. There is benefit in decreasing the heart rate in selected patients with esmolol. Ivabradine is a novel agent for heart rate reduction without decreasing contractility.
引用
收藏
页码:43 / +
页数:20
相关论文
共 50 条
  • [21] Hemodynamic support in septic shock
    Garcia-de-Acilu, Marina
    Mesquida, Jaume
    Gruartmoner, Guillem
    Ferrer, Ricard
    CURRENT OPINION IN ANESTHESIOLOGY, 2021, 34 (02) : 99 - 106
  • [22] SEPTIC SHOCK SYNDROME AND IMMUNOTHERAPY
    OFFENSTADT, G
    GUIDET, B
    VASSAL, T
    SEMAINE DES HOPITAUX, 1991, 67 (45-46): : 2000 - 2008
  • [23] β-Blocker in Septic Shock Management
    Durand, M.
    Louis, H.
    Fritz, C.
    Levy, B.
    Kimmoun, A.
    MEDECINE INTENSIVE REANIMATION, 2019, 28 (02): : 126 - 143
  • [24] Septic Shock: Phenotypes and Outcomes
    Cereuil, Alexandre
    Ronfle, Romain
    Culver, Aurelien
    Boucekine, Mohamed
    Papazian, Laurent
    Lefebvre, Laurent
    Leone, Marc
    ADVANCES IN THERAPY, 2022, 39 (11) : 5058 - 5071
  • [25] Pharmacological treatment of septic shock
    Arrieta, O
    Rodriguez-Reyna, TS
    Sotelo, J
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (05) : 601 - 622
  • [26] Septic shock and septic cardiomyopathy
    Ebelt, H.
    Werdan, K.
    KARDIOLOGE, 2013, 7 (04): : 261 - 266
  • [27] Septic shock and septic cardiomyopathy
    Ebelt, H.
    Werdan, K.
    MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2012, 107 (01) : 24 - 28
  • [28] Septic shock and septic cardiomyopathy
    Ebelt H.
    Werdan K.
    Der Kardiologe, 2013, 7 (4): : 261 - 266
  • [29] SEPSIS AND SEPTIC SHOCK: PATHOPHYSIOLOGICAL AND CARDIOVASCULAR BACKGROUND AS BASIS FOR THERAPY
    De Kock, I.
    Van Daele, C.
    Poelaert, J.
    ACTA CLINICA BELGICA, 2010, 65 (05): : 323 - 329
  • [30] Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock
    Rehberg, Sebastian
    Ertmer, Christian
    Koehler, Gabriele
    Spiegel, Hans-Ulrich
    Morelli, Andrea
    Lange, Matthias
    Moll, Katharina
    Schlack, Katrin
    Van Aken, Hugo
    Su, Fuhong
    Vincent, Jean-Louis
    Westphal, Martin
    INTENSIVE CARE MEDICINE, 2009, 35 (07) : 1286 - 1296